Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes-Reference-Cited by-同舟云学术

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes

Published:2012-09 Issue:9 Volume:14 Page:1056-1066
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European Journal of Heart Failure

Author:

Gheorghiade Mihai¹,Greene Stephen J.²,Filippatos Gerasimos³,Erdmann Erland⁴,Ferrari Roberto⁵,Levy Phillip D.⁶,Maggioni Aldo⁷,Nowack Christina⁸,Mebazaa Alexandre⁹,

Affiliation:

1. Centre for Cardiovascular Innovation; Northwestern University Feinberg School of Medicine; 645 North Michigan Ave., Suite 1006 Chicago IL 60611 USA

2. Department of Medicine; Northwestern University Feinberg School of Medicine; Chicago IL USA

3. Heart Failure Unit, Department of Cardiology; Attikon University Hospital; Athens Greece

4. Herzzentrum der Universität zu Köln; Cologne Germany

5. Department of Cardiology and LTTA Centre; University Hospital of Ferrara and Salvatore Maugeri Foundation; IRCCS Lumezzane Italy

6. Department of Emergency Medicine; Wayne State University School of Medicine; Detroit MI USA

7. ANMCO Research Centre; Florence Italy

8. Global Clinical Development; Bayer Pharma AG; Wuppertal Germany

9. AP-HP, Department of Anaesthesiology and Critical Care Medicine, Hôpital Lariboisière, Paris; Université Paris Diderot, PRES Sorbonne-Paris-Cité, and U942 INSERM; France

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference23 articles.

1. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM);Dickstein;Eur Heart J,2008

2. Acute heart failure syndromes: current state and framework for future research;Gheorghiade;Circulation,2005

3. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation;Hunt;J Am Coll Cardiol,2009

4. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward;Felker;Circ Heart Fail,2010

5. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential;Evgenov;Nat Rev Drug Discov,2006

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-04

2. The efficacy and safety of soluble guanylate cyclase modulation in patients with heart failure: a comprehensive meta-analysis of randomized controlled trials;Scientific Reports;2024-03-24

3. Identification of new multi-substituted 1H-pyrazolo[3,4-c]pyridin-7(6H)-ones as soluble guanylyl cyclase (sGC) stimulators with vasoprotective and anti-inflammatory activities;Bioorganic Chemistry;2024-03

4. The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase;European Respiratory Review;2024-01-31

5. Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode;ESC Heart Failure;2023-12-29